ICH Shifts Strategy to Incorporate The Patient’s Persperctive
The ICH Townhall at the 2024 DIA Europe conference featured insightful discussions on the critical role of the International...
Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Authority FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Protocol Design Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
The ICH Townhall at the 2024 DIA Europe conference featured insightful discussions on the critical role of the International...
Charles River Laboratories and Sanofi have partnered to explore the use of Virtual Control Groups (VCGs) in nonclinical toxicology....
Elemind, a neurotech wellness company, has introduced a revolutionary headband that harnesses advanced neurotechnology to improve sleep quality. The...
Be Biopharma (Be Bio) announced that the FDA has granted Orphan Drug Designation to BE-101, an engineered B Cell...
Long-term follow-up data from the TRANSFORM trial reveals that Breyanzi, a chimeric antigen receptor T-cell (CAR T) therapy, continues...
Legend Biotech Corporation, a leader in cell therapy, announced positive results from its Phase 2 CARTITUDE-2 Cohort D study,...
Merck KGaA, a science and technology leader, is expanding its oncology pipeline with promising new treatments. The company plans...
Positive Results from CatalYm’s GDFATHER Trial CatalYm’s “GDFATHER” Phase 1/2a trial has shown promising results for its lead candidate,...
Bristol Myers Squibb’s ongoing research in non-small cell lung cancer (NSCLC) has yielded promising results in various stages of...
Obsidian Therapeutics presented updated data from the Phase 1 study of OBX-115, an engineered tumor-derived autologous T-cell immunotherapy, at...